Albeit coming from retrospective/real‐world experiences, the potential impact of platinum exposure on the OS of advanced PDAC patients carrying gBRCA1‐2pv [9] or whose tumors display HRD (particularly germline or somatic BRCA1/2 and PALB2 mutations) [14] is well known and has recently been confirmed by our own data in gBRCA1‐2pv both in first and second line, favoring the use of multiagent regimens (platinum‐containing triplets and quadruplets, as opposed to doublets) and as early as possible in the course of metastatic disease (first, as opposed to second or subsequent, line[s]) [10, 13]. This evidence concerns the gene PALB2 and metastatic neoplasm.